Title: Revolutionizing Breast Cancer Treatment: Three Landmark Studies Show Promising Results
Three groundbreaking studies, published almost simultaneously in the New England Journal of Medicine (NEJM) and Nature Medicine, have left an indelible mark on the battle against breast cancer, both in its initial and metastatic stages. These results were presented and discussed at the San Antonio Breast Cancer Symposium.
Destiny06: Anticorpo coniugato triumphs in HER2-low tumors
The first study, Destiny06, published in the NEJM on December 6, solidifies the role of antibody-drug conjugates (ADCs) in treating patients with HER2-low breast cancers, which express low levels of the human epidermal growth factor receptor 2 (HER2). Data demonstrated that even in patients with HER2-low or HER2-ultralow tumors, the ADC trastuzumab deruxtecan, in combination with hormonal therapy, extends the period without disease progression by an average of five months compared to chemotherapy.
EMBER-3: A new hope for metastatic breast cancer
Significant progress in therapies for metastatic breast cancers emerged from the results of the second study, EMBER-3, also published in the NEJM on December 10. Imlunestrant, an oral selective estrogen receptor degrader (SERD), showed promising results when paired with the chemotherapy drug Abemaciclib in patients with ER+ HER2- advanced breast cancer. In patients who had previously received endocrine therapy, the combination of Imlunestrant and Abemaciclib led to an approximate four-month improvement in progression-free survival compared to standard therapy.
Roche’s Nivolumab revolutionizes neo-adjuvant therapy
The study published in Nature Medicine marks a significant step forward in neo-adjuvant therapy, administered before surgery to reduce tumor size and make it more surgically manageable. The research demonstrated that the immunotherapy drug Nivolumab enhances the efficacy of neo-adjuvant chemotherapy without worsening its side effects in women with high-risk, ER+ HER2- breast cancer. Furthermore, researchers identified specific subgroups of patients, characterized by high levels of infiltrating lymphocytes and PD-L1 expression, who are more likely to respond and benefit from the combination of Nivolumab and neo-adjuvant chemotherapy.
